KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Novavax (NVAX) Other Operating Expenses (2019 - 2025)

Novavax has reported Other Operating Expenses over the past 10 years, most recently at $22.9 million for Q4 2025.

  • Quarterly results put Other Operating Expenses at $22.9 million for Q4 2025, down 37.52% from a year ago — trailing twelve months through Dec 2025 was $170.9 million (down 15.71% YoY), and the annual figure for FY2024 was $51.9 million, changed.
  • Other Operating Expenses for Q4 2025 was $22.9 million at Novavax, down from $118.5 million in the prior quarter.
  • Over the last five years, Other Operating Expenses for NVAX hit a ceiling of $434.6 million in Q3 2022 and a floor of $14.1 million in Q1 2025.
  • Median Other Operating Expenses over the past 4 years was $57.5 million (2023), compared with a mean of $101.3 million.
  • Peak annual rise in Other Operating Expenses hit 124.19% in 2023, while the deepest fall reached 79.42% in 2023.
  • Novavax's Other Operating Expenses stood at $181.8 million in 2022, then decreased by 14.74% to $155.0 million in 2023, then plummeted by 76.34% to $36.7 million in 2024, then plummeted by 37.52% to $22.9 million in 2025.
  • The last three reported values for Other Operating Expenses were $22.9 million (Q4 2025), $118.5 million (Q3 2025), and $15.3 million (Q2 2025) per Business Quant data.